TABLE 3.

Association of SNPs of candidate genes and odds ratio to EOAD risk.

Gene	SNP	minor allele	MAF (case/control)	OR	95%CI		P allele
HLA-DRB1	rs9271058	A	0.224/0.124	2.038	1.17–3.56		0.011
CD2AP	rs9473117	C	0.102/0.134	0.733	0.36–1.50		0.393
PTK2B	rs73223431	T	0.337/0.249	1.533	0.95–2.47		0.077
Gene	SNP	Dominant model (adjusted)			Recessive model (adjusted)
		OR	95%CI	P	OR	95%CI	P
HLA-DRB1	rs9271058	2.563	1.10–5.99	0.03	2.23	0.23–20.99	0.483
CD2AP	rs9473117	0.327	0.12–0.93	0.035	0.69	0.08–5.88	0.231
PTK2B	rs73223431	3.108	1.36–7.09	0.007	2.603	0.54–12.64	0.235
Gene	SNP	Additive model (adjusted)			Overdominant model (adjusted)
		OR	95%CI	P	OR	95%CI	P
HLA-DRB1	rs9271058	2.23	1.07–4.68	0.033	2.363	1.01–5.56	0.049
CD2AP	rs9473117	0.39	0.16–0.93	0.034	0.387	0.13–1.16	0.09
PTK2B	rs73223431	2.438	1.26–4.71	0.008	2.523	1.11–5.72	0.027

EOAD, early onset Alzheimer’s diseases; SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval. P allele was examined using the Chi-square test. P was adjusted for gender and age with binary logistic regression. Bold indicates statistically significant values.